{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:45:41Z","timestamp":1782729941967,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16064-5","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:44:31Z","timestamp":1777985071000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated DNA and RNA profiling refines prognostic stratification independent of therapeutic actionability in cholangiocarcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Julie A.","family":"Vendrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Dalmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cabello-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Colinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Solassol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"16064_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"JW Valle","year":"2010","unstructured":"Valle JW, Wasan HS, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"16064_CR2","first-page":"845","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1). Lancet Gastroenterol Hepatol. 2022;7:845\u201357.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"16064_CR3","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab plus chemotherapy in advanced biliary tract cancer (KEYNOTE-966). Lancet. 2023;401:1853\u201365.","journal-title":"Lancet"},{"key":"16064_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline. Ann Oncol. 2023;34:127\u201340.","journal-title":"Ann Oncol"},{"key":"16064_CR5","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas. Clin Cancer Res. 2018;24:4154\u201361.","journal-title":"Clin Cancer Res"},{"key":"16064_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/PO.18.00414","volume":"4","author":"J Cao","year":"2020","unstructured":"Cao J, Hu J, Liu S, Meric-Bernstam F, Abdel-Wahab R, Xu J, et al. Genomic landscape of intrahepatic cholangiocarcinoma: East\u2013West comparison. JCO Precis Oncol. 2020;4:557\u201369.","journal-title":"JCO Precis Oncol"},{"key":"16064_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"16064_CR8","first-page":"1599","volume":"150","author":"A Stenzinger","year":"2024","unstructured":"Stenzinger A, Warth A, Endris V, Goeppert B, Klauschen F, Denkert C, et al. The evolving role of next-generation sequencing in cholangiocarcinoma. J Cancer Res Clin Oncol. 2024;150:1599\u2013612.","journal-title":"J Cancer Res Clin Oncol"},{"key":"16064_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","volume":"144","author":"D Sia","year":"2013","unstructured":"Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals two classes with distinct outcomes. Gastroenterology. 2013;144:829\u201341.","journal-title":"Gastroenterology"},{"key":"16064_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","volume":"73","author":"R Montal","year":"2020","unstructured":"Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabro R, Pinyol R, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73:315\u201327.","journal-title":"J Hepatol"},{"key":"16064_CR11","doi-asserted-by":"publisher","first-page":"e2100510","DOI":"10.1200\/PO.21.00510","volume":"6","author":"K Mody","year":"2022","unstructured":"Mody K, Gupta R, Bekaii-Saab T, Arora SP, Reyes A, Pant S, et al. Clinicogenomic and transcriptomic profiling in biliary tract cancers. JCO Precis Oncol. 2022;6:e2100510.","journal-title":"JCO Precis Oncol"},{"key":"16064_CR12","doi-asserted-by":"crossref","first-page":"12827","DOI":"10.1038\/s41598-017-12679-8","volume":"7","author":"JA Vendrell","year":"2017","unstructured":"Vendrell JA, Solassol J, Senal R, Audran P, Banneau G, Evrard A, et al. Multiplex detection of gene fusions in solid tumors using anchored multiplex PCR. Sci Rep. 2017;7:12827.","journal-title":"Sci Rep"},{"key":"16064_CR13","doi-asserted-by":"crossref","unstructured":"Thomas QD, Vendrell JA, Khellaf L, Cabello-Aguilar S, Grand D, Escudi\u00e9 F et al. Artificial intelligence-driven microsatellite instability profiling reveals distinctive genetic features in patients with lung cancer. Cancer. 2025;e35882.","DOI":"10.1002\/cncr.35882"},{"key":"16064_CR14","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3390\/cancers12082224","volume":"12","author":"P Blateau","year":"2020","unstructured":"Blateau P, Coyaud E, Laurent E, B\u00e9ganton B, Ducros V, Chauchard G, et al. TERT promoter mutation as an independent prognostic marker for poor prognosis MAPK-inhibitor-treated melanoma. Cancers. 2020;12:2224.","journal-title":"Cancers"},{"key":"16064_CR15","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1093\/bioinformatics\/btz797","volume":"36","author":"F Escudi\u00e9","year":"2020","unstructured":"Escudi\u00e9 F, Van Goethem C, Grand D, Vendrell J, Vigier A, Brousset P, Evrard SM, et al. MIAmS: microsatellite instability detection on NGS amplicons data. Bioinformatics. 2020;36:1915\u20136.","journal-title":"Bioinformatics"},{"key":"16064_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.omtn.2022.09.009","volume":"30","author":"S Cabello-Aguilar","year":"2022","unstructured":"Cabello-Aguilar S, Vendrell JA, Van Goethem C, Brousse M, Goz\u00e9 C, Frantz L, Solassol J. ifCNV: a novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets. Mol Ther Nucleic Acids. 2022;30:174\u201383.","journal-title":"Mol Ther Nucleic Acids"},{"key":"16064_CR17","doi-asserted-by":"publisher","first-page":"12510","DOI":"10.1038\/s41598-017-12679-8","volume":"7","author":"JA Vendrell","year":"2017","unstructured":"Vendrell JA, Taviaux S, B\u00e9ganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazi\u00e8res J, Costes V, Pujol JL, Brousset P, Rouquette I, Solassol J. Detection of known and novel ALK fusion transcripts in lung cancer using next-generation sequencing approaches. Sci Rep. 2017;7:12510.","journal-title":"Sci Rep"},{"key":"16064_CR18","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1093\/nar\/gkad352","volume":"51","author":"JP Villemin","year":"2023","unstructured":"Villemin JP, Bassaganyas L, Pourquier D, Boissi\u00e8re F, Cabello-Aguilar S, Crapez E, et al. Inferring ligand\u2013receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR. Nucleic Acids Res. 2023;51:4726\u201342.","journal-title":"Nucleic Acids Res"},{"key":"16064_CR19","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29:1895\u2013902.","journal-title":"Ann Oncol"},{"key":"16064_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228\u201339.","journal-title":"N Engl J Med"},{"key":"16064_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796\u2013807.","journal-title":"Lancet Oncol"},{"key":"16064_CR22","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7:1669\u201377.","journal-title":"JAMA Oncol"},{"key":"16064_CR23","doi-asserted-by":"publisher","first-page":"e2300544","DOI":"10.1200\/PO.23.00544","volume":"8","author":"S Makawita","year":"2024","unstructured":"Makawita S, Choo SP, Lim KH, Job S, Zucman-Rossi J, Valle JW. Comprehensive immunogenomic profiling of IDH1\/2-altered intrahepatic cholangiocarcinoma. JCO Precis Oncol. 2024;8:e2300544.","journal-title":"JCO Precis Oncol"},{"key":"16064_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","volume":"40","author":"L Dong","year":"2022","unstructured":"Dong L, Zeng Z, Zhao J, Chen Y, Cai J, Wu X, et al. Proteogenomic characterization of KRAS-TP53 co-mutated cholangiocarcinoma. Cancer Cell. 2022;40:70\u2013e8715.","journal-title":"Cancer Cell"},{"issue":"7693","key":"16064_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"key":"16064_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41423-023-00980-8","volume":"20","author":"Y Gu","year":"2023","unstructured":"Gu Y, Zhang Z, ten Dijke P. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Cell Mol Immunol. 2023;20:318\u201340.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"16064_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41392-025-02473-8","volume":"10","author":"K Choucair","year":"2025","unstructured":"Choucair K, Imtiaz H, Uddin MH, Nagasaka M, Al-Hallak MN, Philip PA, El-Rayes B, Pasche BC, Azmi AS. Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges. Signal Transduct Target Ther. 2025;10(1):385.","journal-title":"Signal Transduct Target Ther"},{"key":"16064_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41467-024-44748-8","volume":"15","author":"Z Fan","year":"2024","unstructured":"Fan Z, Zou X, Wang G, Liu X, Zhang P, Li Y, et al. CORE-37: a compact transcriptomic classifier for cholangiocarcinoma. Nat Commun. 2024;15:484.","journal-title":"Nat Commun"},{"key":"16064_CR29","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.31803","volume":"74","author":"Y Wada","year":"2021","unstructured":"Wada Y, Shimada M, Yamamura K, Nakao Y, Harada S, Yoshikawa Y, et al. An eight-gene prognostic signature for intrahepatic cholangiocarcinoma. Hepatology. 2021;74:1371\u201383.","journal-title":"Hepatology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16064-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16064-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16064-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:57:13Z","timestamp":1782727033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16064-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16064"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16064-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Montpellier University Hospital Ethics Committee (IRB\/CPP No. 2023-CCA-01). All patients provided informed consent for molecular testing in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"781"}}